No. RFA-DA-25-060 · National Institutes of Health
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
Not reimbursement-only
“Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.” — From the announcement
- Award range
- Up to $1,500,000
- Expected awards
- Not specified
- Application deadline
- Mar 5, 2027
- Posted
- Jan 17, 2024
- Last verified
- 5 days ago
At a glance
AI summaryThis program funds highly collaborative research on HIV and substance use, including basic, epidemiologic, clinical, intervention, and implementation studies. It is open to U.S. organizations and requires a multiple PD/PI team of 3 to 6 investigators; foreign organizations cannot apply, though foreign components in U.S. applications are allowed. NIDA expects to fund one to two awards, with direct costs up to $1.5 million per year and a project period of up to 5 years. No cost sharing is required, and applications must fit NIDA and NIH HIV research priorities; projects focused only on alcohol, only on developing a product or device, only on certain clinical trials, only on observational/genetic/comparative effectiveness studies, or research outside the U.S. are not responsive.
AI-generated summary — verify against the announcement
What it funds
Official description from grants.gov
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
Who can apply
- City or township governments
- County governments
- For-profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Others
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Small businesses
- Special district governments
- State governments
Program history
USASpending.govAssistance listing 93.279 · Drug Use and Addiction Research Programs
Real awards this federal program has made — the whole assistance listing (93.279), not just this notice.
| Fiscal year | Awards | Median award | Middle half |
|---|---|---|---|
| FY 2026 (so far) | 428 | $422,523 | $183,034 – $700,682 |
| FY 2025 | 588 | $709,054 | $348,214 – $1,489,059 |
| FY 2024 | 714 | — | — |
| FY 2023 | 724 | — | — |
| FY 2022 | 740 | — | — |
| FY 2021 | 606 | — | — |
For comparison, this notice advertises Up to $1,500,000.
Dollar figures are based on the 1,000 most recent awards we store, not all 3,800 — award counts are complete.
- FLORIDA INTERNATIONAL UNIVERSITY $7,372,834 · FY 2025
- BETH ISRAEL DEACONESS MEDICAL CENTER, INC. $7,081,684 · FY 2025
- UNIVERSITY OF WASHINGTON $7,003,822 · FY 2025
- REACX PHARMACEUTICALS, INC. $6,900,000 · FY 2025
- WORCESTER POLYTECHNIC INSTITUTE $6,889,914 · FY 2025
Source: USASpending.gov · refreshed Aug 18, 2026